A 66-year-old man with IMT bone metastasis accompanied by GCC2-ALK fusion and another man with pulmonary IMT underwent postoperative disease progression with STRN-ALK fusion both obtained PR following treatment with ensartinib (21, 22). This evidence concerns the gene GCC2 and inflammatory myofibroblastic tumor.